Αποτελέσματα Αναζήτησης
28 Δεκ 2017 · In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma ...
11 Μαΐ 2023 · In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with refractory large B-cell lymphoma (LBCL). Here, we assessed outcomes in ZUMA-1 after 5 years of follow-up.
5 Ιουν 2023 · Conclusions. At a median follow-up of 47.2 months, axi-cel as second-line treatment for patients with early relapsed or refractory large B-cell lymphoma resulted in significantly longer overall...
26 Μαΐ 2019 · Conclusions: The 2-y follow-up of ZUMA-1 demonstrates that axi-cel can induce high rates of durable responses with a manageable safety profile for pts ≥ and < 65 y. Axi-cel offers substantial clinical benefit for older pts with refractory LBCL who otherwise have limited treatment options. Clinical trial information: NCT02348216.
4 Ιαν 2024 · ZUMA-1 pivotal cohorts 1 + 2 (N = 101) demonstrated high, durable responses (83% objective response rate [ORR]; 58% complete response [CR] rate), and a manageable safety profile with long-term...
Here we report long-term activity and safety outcomes of the ZUMA-1 study. Methods: ZUMA-1 is a single-arm, multicentre, registrational trial at 22 sites in the USA and Israel. Eligible patients were aged 18 years or older, and had histologically confirmed large B-cell lymphoma-including diffuse large B-cell lymphoma, primary mediastinal B-cell ...
1 Ιουν 2018 · These results led to its approval by the US FDA for the treatment of adult pts with relapsed or refractory large B cell lymphoma after ≥ 2 prior lines of therapy. Here, we examined responses over time in phase 2 of ZUMA-1.
